PAS-004 demonstrates preliminary clinical activity as a monotherapy in patients with heavily pre-treated, refractory solid ...

Curogen, one of South Korea's leading biotechnology companies focused on nanotechnology-based treatments for autoimmune diseases, today announced a series of strategic appointments that strengthen its ...

Immunic, Inc. , a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation ...

As shown in table 2, both OS and CBR values were in line or higher than those reported in the treatment arm of the ASCENT ...

An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

Over the succeeding years, News Corp offloaded its coupon-insert businesses, News America Marketing, as well as its Australian satellite-television company, Foxtel. It has also made headway in ...

Bristol-Myers Squibb Co. will pay BioNTech SE as much as $11.1 billion to license a next-generation cancer drug, as ...

BioCryst will present four abstracts at the meeting: Impact of Berotralstat on Quality of Life among Patients with Hereditary ...

Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the ability to ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...

The primary endpoints of TROPION-Lung02 are dose-limiting toxicities and treatment-emergent adverse events. Secondary endpoints include ORR, DoR, PFS as assessed by investigator, overall survival, ...

Novartis has presented new data from the Phase III NATALEE trial at ASCO 2025, showcasing Kisqali’s ability to reduce the risk of recurrence in ...